Rakesh Gopinathannair, MD, lead author of a recent American Heart Association scientific statement on cardiac arrhythmias associated with COVID-19, reviewed the latest science associated with this important topic.

Clyde Yancy, MD, spoke with Cardiovascular Business about how the treatment of heart failure with preserved ejection fraction (HFpEF) has evolved in recent years.

Heart Rhythm Society President Kenneth A. Ellenbogen, MD, detailed a new advocacy group focused on improving EP reimbursements, patient care and access. “If you’re not at the table, you’re on the menu," he said.

Approximately 800,000 strokes occur each year in the United States alone. A majority of people survive, due in part to key advances in patient care over the years, but they often go forward without receiving the long-term help they need to recover and thrive. 

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

The heightened risks were even seen in women who were never diagnosed with a psychiatric disorder. It remains unclear why the same trend was not seen in men.

Cardiovascular Business spoke with cardiologist Daniel Judge, MD, about the long-term benefits of acoramidis, a new drug therapy that just received FDA approval to treat transthyretin amyloid cardiomyopathy.

Martha Gulati, MD, spoke to Cardiovascular Business at AHA Scientific Sessions 2024 about key developments in obesity treatment and CVD prevention.